Previous 10 | Next 10 |
LEXINGTON, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients sufferi...
Keros Therapeutics (KROS +3.8%) announces the appointment of Simon Cooper, M.B.B.S, as Keros' Chief Medical Officer, or CMO, effective as of August 2, 2021. Dr. Cooper most recently served as the Senior Vice President, Chief Medical Officer of Kadmon (NASDAQ:KDMN). Dr. Cooper is succeeding Cl...
LEXINGTON, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and muscu...
Gainers: Entera Bio (ENTX) +56%. Orphazyme (ORPH) +47%. Bellerophon Therapeutics (BLPH) +26%. HUTCHMED (HCM) +11%. Evaxion Biotech (EVAX) +8%.Losers: Gemini Therapeutics (GMTX) -32%. Second Sight Medical Products (EYES) -19%. Millendo Therapeutics (MLND) -17...
tonaquatic/iStock via Getty Images Keros Therapeutics (KROS) says it will extend the phase 2 treatment duration of myelodysplastic syndromes ("MDS") candidate KER-050 from 12 weeks to up to two years to measure duration of response. Preliminary results released today indicated that as of...
LEXINGTON, Mass., June 22, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and muscu...
Multiple poster presentations demonstrate that ALK2 inhibition lowered hepcidin levels and improved iron homeostasis in preclinical models of anemia and iron overload. Poster presentation demonstrates that KER-050 had effects on multiple stages of erythroblast maturation (both...
LEXINGTON, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and muscul...
Keros Therapeutics (KROS) announces the issuance of U.S. patent for the use of therapeutic proteins in treatment of musculoskeletal disorders.The United States Patent and Trademark Office (“USPTO”) has issued the company U.S. Patent No. 11,013,785.The patent contains 2...
LEXINGTON, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and muscul...
News, Short Squeeze, Breakout and More Instantly...
Keros Therapeutics Inc. Company Name:
KROS Stock Symbol:
NASDAQ Market:
Keros Therapeutics Inc. Website:
2024-06-25 22:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-24 17:15:02 ET Oppenheimer analyst issues OUTPERFORM recommendation for KROS on June 24, 2024 04:14PM ET. KROS was trading at $46.48 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy recomme...
LEXINGTON, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patie...